Restricted Antimicrobials


e.  Linezolid (Zyvox)


Linezolid belongs to a new class of synthetic antimicrobials, the oxazolidinones. Linezolid has activity against Enterococcus faecium, Enterococcus faecalis, MSSA, MRSA, MRSE and many Streptococcal spp. Linezolid is available as an intravenous and oral preparation. After oral administration, linezolid is completely absorbed and has 100% bioavailability. Therefore, in patients tolerating oral medications linezolid will be administered orally [600 mg PO/IV BID] [Pediatrics: 10 mg/kg q8h PO/IV]


Criteria for use:

  1. Significant vancomycin resistant Enterococcus faecium (VREF) infections i.e. isolated from a sterile site: blood, abscess
  1. Infections due to MRSA if the patient has a well documented intolerance of vancomycin (Red man syndrome is not a serious intolerance)


Linezolid cannot be released for the treatment of the following:



Consideration for use:


Linezolid's oral formulation is 100% bioavailable.  Whenever possible patients should receive po voriconazole.

   Standard adult dose:  600mg po/IV q12h

Dosage adjustment is unneccessary in renal or hepatic insufficiency.


For approval of restricted antimicrobials contact ID pharmacy at 443-9421